Sana Klinikum Offenbach GmbH — Clinical Trial Site

20 Registered trials

8 Currently recruiting

Organisation

Sana Klinikum Offenbach GmbH

Location

Offenbach Am Main, Germany

Identifier

ORG-100041308

Address

Starkenburgring 66, 63069, Germany

Departments

Ambulantes Onkologisches Zentrum
Clinic for Gynaecology and Obstetrics
Department of Gynecology and Obstetrics
Frauenklinik
Gastroenterologie, Gastrointestinale Onkologie und Interventionelle Endoskopie
Hämatologie und internistische Onkologie
Klinik für Gynäkologie und Geburtshilfe
KLINIK FÜR HÄMATOLOGIE UND INTERNISTISCHE ONKOLOGIE
Klinik für Pneumologie / Thoraxzentrum Rhein-Main
Medizinische Klinik IV
Medizinische Klinik IV für Hämatologie und internistische Onkologie
Medizinische Klinik IV Klinik für Haematologie und internistische Onkologie
Medizinische Klinik IV, Hämatologie und internistische Onkologie
N/A
Onkologisches Centrum Offenbach, Brust- und Gynäkologisches Krebszentrum
Sana Klinikum Offenbach

Clinical trials at this site (20)

Search interface

Study of Volrustomig as Monotherapy or in Combination with Anti- cancer Agents in Participants with Advanced/Metastatic Solid Tumors Recruiting

2025-523947-36-00 Sub-study 5: Unresectable Pleural Mesothelioma (Volrust 4 2026-06-10
NoLEEta - Phase III non-inferiority trial of chemotherapy de-escalation in hormone receptorpositive, Her2-negative, intermediate-risk early … Recruiting

2025-520979-13-00 Patients with HR+ HER2- early breast cancer at intermed 5 2025-12-18
Osimertinib plus chemotherapy as 1st line therapy in stage IV NSCLC patients with atypical EGFR mutations (AIO-TRK/YMO-0324) Recruiting

2024-516790-78-00 stage IV NSCLC (non-small-cell lung cancer) 4 2025-09-04
Phase 2 Study of Adagrasib Monotherapy and in Combination With Pembrolizumab and Phase 3 Study of Adagrasib in Combination with Pembrolizuma… Recruiting

2023-508922-83-00 Advanced Non-Small Cell Lung Cancer 10 2021-03-17
A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-line Treatment of PD-L1-high Metastatic Non-small Cell Lung… Recruiting

2024-517780-24-00 Lung Cancer 5 2025-09-18
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician’s Choice in Patients With Triple Negative Breast Cancer … Recruiting

2024-512279-10-00 Triple Negative Breast Cancer 5 2024-11-25
A Global Multicenter, Open Label, Randomized Phase 3 Registrational Study of Lisaftoclax (APG-2575) in Previously Treated Patients with Chro… Recruiting

2023-508005-24-00 Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 5 2024-08-01
A Phase I/II First-In-Human Clinical Trial to Evaluate the Safety, Tolerability and Anti-Tumor Activity of IMA402, a Bispecific T Cell-Engag… Recruiting

2022-503133-54-00 Solid Tumors 7 2023-08-09
Tuvusertib (M1774) in Combination with Cemiplimab in Participants with Non-Squamous NSCLC (DDRiver NSCLC 322) Ended

2022-502010-85-00 Non-Squamous Non-Small Cell Lung Cancer 9 2023-12-20
AFAMOSI: Prospective, randomized, multicenter Phase IV study to evaluate the efficacy and safety of afatinib followed by osimertinib compare… Ended

2024-511625-55-00 EGFRmutated/T790M Mutation negative non-squamous NSCLC 6 2022-11-30
Phase 1 / 2 Study Evaluating MCLA-129 in Advanced NSCLC Ended

2024-514461-19-00 Solid Tumors 9 2021-09-09
A study on the efficacy and safety of cisplatin/etoposide and concomitant radiotherapy in combination with durvalumab, an immunotherapy, in … Ended

2024-513433-20-00 Limited Disease Small Cell Lung Cancer 4 2020-12-16
Sacituzumab Govitecan in primary HER2-negative breast cancer (SASCIA) Ended

2023-510390-33-00 HER2-negative breast cancer patients with high relapse 5 2020-10-23
Short course radiotherapy versus chemoradiotherapy, followed by consolidation chemotherapy, and selective organ preservation for MRI-defined… Ended

2024-511577-29-01 intermediate and high-risk rectal cancer 5 2020-03-13
Adjuvant Dynamic marker - Adjusted Personalized Therapy comparing endocrine therapy plus ribociclib versus chemotherapy in intermediate-risk… Ended

2024-515769-32-00 HR+/HER2- early breast cancer 5 2019-07-02
Phase III study of pembrolizumab for high-risk early-stage ER+/HER2– breast cancer Ended

2023-506921-12-00 ER+/HER2- Breast Cancer 5 2018-12-27
Olaparib as adjuvant treatment in patients with germline BRCA mutated high risk HER2negative primary breast cancer. Ended

2024-511096-15-00 Breast Cancer 5 2014-08-01
Thoracic Radiotherapy plus Durvalumab in Elderly and/or frail NSCLC stage III patients unfit for chemotherapy - Employing optimized (hypofra… Ended

2024-513948-28-00 unresectable stage III NSCLC (Non–small-cell lung cance 4 2020-05-08
This is a phase III randomised, double-blind, placebo-controlled, multicentre, global study to assess the effectiveness and safety of standa… Ended

2022-502747-35-00 Newly diagnosed advanced (FIGO stage III-IV) high grade 5 2019-02-18
A Randomized, Double-Blind, Phase III Clinical Trial of Neoadjuvant Chemotherapy with Atezolizumab or Placebo in Patients with Triple-Negati… Ended

2023-508472-11-00 Patients with early breast cancer 5 2018-06-13